Become A Featured Company

GB Sciences (GBLX): A Grow Business with a Moonshot in Biopharma

Ryan Allway

January 6th, 2017

News, Top News

GB Sciences Inc. (OTCQB: GBLX) has spent the past year narrowing its focus and improving its balance sheet to prepare for growth. After securing cultivation and production licenses in Nevada, the company pivoted from an agricultural technology provider to a producer of medical cannabis and an innovator in cannabinoid research and development. The new focus provides investors with both stable cash flow and long-term potential.

In this article, we will take a closer look at the company’s new strategy and why investors may want to consider the stock as it reaches an inflection point.

Near-term Cash Flow

GB Sciences acquired its initial cultivation license in late-2014 and leveraged that to obtain additional licenses for production and dispensaries. Unlike many producers, the company standardizes its cannabis-based products through tissue replication technology to reduce genetic drift and ensures controlled growth conditions in sterile cleanrooms. This science-based approach is coupled with strict process controls to create a cultivation and production system that is compliant with cGMP and IS0 9001:2015 quality control systems. GB Sciences technology and process controls ensure safety and consistency of production for both bulk sale and to support its research and development programs.

The company very recently opened its Las Vegas production facility in January, which should begin generating cash flow in the first quarter of 2017. GB Sciences also recently announced the acquisition of two more Nevada licenses that will be folded into the Las Vegas production facility, expanding the scope of the business to include oil extraction/production as well as increasing the company’s legal cannabis production capacity.

The company is actively applying for a cultivation and production license in California that it hopes to secure within the next 12 months. The state’s existing medical marijuana program is the largest in the country, making it an important market to target over the near-term.

Over the coming years, GB Sciences hopes to develop a multi-state footprint with licenses in California, Texas, Pennsylvania and Florida. The footprint will enable the company to develop a nationwide brand with a consistent quality and user experience. At the same time, these activities should help generate sufficient cash flow to finance clinical trials without relying as heavily on external fundraising that could be dilutive to shareholders.

Biopharma Moonshot

GB Sciences provides investors with significant upside potential through its biopharmaceutical research and development. While many researchers focus on isolating specific cannabinoids, the company aims to harness the so-called ‘entourage effect’ of multiple cannabinoids in treating serious medical conditions. Research has shown that cannabinoids tend to work in conjunction to effect outcomes, which could make combinations more efficacious.

In October, the company filed the first of several patents covering complex cannabinoid-containing mixtures capable of enhancing dopamine secretion and protecting neurons from mitochondria-induced free radical damage occurring with Parkinson’s disease, Alzheimer’s disease, Lewy Body Dementia, and Huntington’s disease, among others. The company hopes to start an FDA-sponsored pilot study over the next 12 months targeting Parkinson’s disease. In December, GB Sciences also licensed a patent to develop new cannabis-based therapies for the treatment of heart disease.

The company’s Chief Science Officer, Dr. Andrea Small-Howard, has fifteen years of experience studying cannabinoids and the endocannabinoid system, immunology, and cancer treatments; as well as executive experience in the biopharmaceutical industry where she supervised research and development, manufacturing, and quality control divisions. She took the lead in obtaining regulatory approvals from the U.S. Food & Drug Administration (“US FDA”) and multiple international regulatory agencies, and has recently assisted other state jurisdictions in developing medical cannabis regulations. She is supported by three universities and a CRO that work with the company to conduct research and ultimately bring biopharmaceutical products to market. By leveraging these partners and advisors, the company has a real shot at developing meaningful drugs in the space.

Looking Ahead

GB Sciences Inc. (OTCQB: GBLX) has spent the past year narrowing its focus and improving its balance sheet. After raising $6 million in fresh capital, the company is ready to open a cultivation and production facility in Nevada next month and begin generating near-term cash flow. The company’s research and development team has also started to file patents and is gearing up to bring valuable cannabinoid-based drugs to market over the long-term.

For more information, visit the company’s website at www.growblox.com.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

Network Partners

Follow Us on Social Media

LinkedIn

About CFN Media Group

CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.

Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.

Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer

loading